MR-2034

MR-2034
Clinical data
Other names	MR2034; Mr-2034; (–)-MR-2033; (–)-MR2033
Drug class	κ-Opioid receptor agonist; Hallucinogen
ATC code	None;
Identifiers
	IUPAC name (1R,9R)-1,13-dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol;
CAS Number	57236-85-8;
PubChem CID	123980;
ChemSpider	110499;
CompTox Dashboard (EPA)	DTXSID20972735 ;
Chemical and physical data
Formula	C19H27NO2
Molar mass	301.430 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC1[C@H]2CC3=C([C@@]1(CCN2C[C@H]4CCCO4)C)C=C(C=C3)O;
	InChI InChI=1S/C19H27NO2/c1-13-18-10-14-5-6-15(21)11-17(14)19(13,2)7-8-20(18)12-16-4-3-9-22-16/h5-6,11,13,16,18,21H,3-4,7-10,12H2,1-2H3/t13?,16-,18-,19-/m1/s1; Key:NLKLXMMOJZHSCB-SENCRUMESA-N;

MR-2034, or Mr-2034, also known as (–)-MR-2033, is a selective κ-opioid receptor (KOR) agonist of the benzomorphan family. Unlike other benzomorphan KOR agonists like cyclazocine and alazocine, MR-2034 does not also act on sigma receptors. In addition to the KOR, it has affinity for the μ-opioid receptor (MOR), but does not activate this receptor. The drug produces dose-dependent hallucinogenic and dysphoric effects in humans, as well as other effects such as dizziness, anxiety, and sedation. These effects can be blocked by the non-selective opioid receptor antagonist naloxone. The preceding findings led to the conclusion that the hallucinogenic and dysphoric effects of benzomorphans are mediated by the KOR rather than by sigma receptors. MR-2034 was first described in the scientific literature by 1975 and its hallucinogenic effects in humans were described in 1986.